2026-08-05T15:43:12Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/203812024-11-28T23:05:02Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967col_20.500.12105_16968

00925njm 22002777a 4500 dc Martinez-Lopez, J author Sanchez-Vega, B author Barrio, S author Cuenca, I author Ruiz-Heredia, Y author Alonso, R author Rapado, I author Marin, C author Cedena, M-T author Paiva, B author Puig, N author Mateos, M-V author Ayala, R author Hernandez, M-T author Jimenez, C author Rosinol, L author Martinez, R author Teruel, Ana Isabel author Gutierrez, N author Martin-Ramos, Maria-Luisa author Oriol, A author Bargay Lleonart, Joan author Blade, J author San-Miguel, J author Garcia-Sanz, R author Lahuerta, J-J author 2017-06 Martinez-Lopez J, Sanchez-Vega B, Barrio S, Cuenca I, Ruiz-Heredia Y, Alonso R, et al. Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma [letter]. Leukemia. 2017 Jun;31(6):1446-9. Epub 2017 Feb 17. 10.1038/leu.2017.58 1476-5551 0887-6924 Leukemia http://hdl.handle.net/20.500.13003/10944 28210002 L614736600 2-s2.0-85014659967 http://hdl.handle.net/20.500.12105/20381 402832700025 Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma